ASH 2024 Summary: Highlights in CML

2024 ASH Annual Meeting Insights Hub

J. Yang

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

ASH 2024 Review: Practice-Changing Updates in the Management of CML

Cleveland Clinic Taussig Cancer Institute

A. Jain

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

Year in Review 2024: CML Highlights

Oncology 2024 Year in Review

J. Cortés

Critical Re-Evaluation of Established Practices in CML Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

Experts Discuss How They Use Asciminib in Their CML Practice

MyCancerHaven

R. Vij, J. Zeidner

FDA Approved First Oral Solution of Imatinib

Winship Cancer Institute - Emory University

A. Abousaud

Efficacy and Safety of Asciminib in Ph+ CML

Luke Fletcher

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes Among Pat…

Insights from 2023 ASH Annual Meeting

E. Atallah

Current Treatment Landscape in Myeloid Malignancies

Houston Methodist

S. Shah

Updates on Myeloproliferative Neoplasms Including CML

Winship Cancer Institute - Emory University

A. Hunter

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

Controversies in the Management of CML in 2024

Indy Hematology Review

R. Larson